STOCK TITAN

NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announced that CEO Justin Hall will present a company overview at the virtual Sequire Biotechnology Conference on February 2 at 2:30 p.m. Eastern time. Avenova® unit sales achieved substantial growth in Q4 2022, indicating a positive trajectory for the company. In 2023, NovaBay plans to focus on its effective wound care products, anticipating significant contributions to revenue. An archived presentation will be accessible on the NovaBay website. Additionally, the company will report its 2022 financial results on March 23, 2023.

Positive
  • None.
Negative
  • None.

EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that Justin Hall, CEO, will present a company overview at the virtual Sequire Biotechnology Conference on Thursday, February 2 at 2:30 p.m. Eastern time. To register for the event, visit the Sequire Biotechnology website.

“We closed 2022 with one of our best quarters ever for Avenova® unit sales. Looking into 2023, we are increasing our focus on our safe, effective wound care products, which we expect will become an important contributor to our business,” said Mr. Hall. “We are excited to share an update on our opportunities with investors attending this conference.”

An archived webcast of the presentation will be available on the NovaBay website. NovaBay will report 2022 fourth quarter and full year financial results on March 23, 2023.

About Sequire

Sequire is a premier investor intelligence and communications platform where companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. More information is available at srax.com and mysequire.com.

About NovaBay Pharmaceuticals, Inc.:

NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and skincare products. NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash Solution, is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to eyecare consumers through online distribution channels such as Amazon. DERMAdoctor® offers more than 30 OTC dermatologist-developed skincare products through the DERMAdoctor website, well-known traditional and digital beauty retailers, and international distributors. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne® brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase® brand is distributed in China by Pioneer Pharma (Hong Kong) Company Ltd.

NovaBay Pharmaceuticals Forward-Looking Statements

Except for historical information herein, matters set forth in this press release may be forward looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our business strategies, current partnerships, marketing efforts, and any future revenue that may result from such partnerships and related marketing initiatives, as well as generally the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the possibility that the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, and revenues will not be sufficient to meet the Company’s cash needs. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings and Registration Statement on Form S-1 filing with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Socialize and Stay Informed on NovaBays Progress
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website

Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com
Avenova.com

DERMAdoctor Purchasing Information
For DERMAdoctor purchasing information:
Please call 877-337-6237 or email service@dermadoctor.com
DERMAdoctor.com

NovaBay Contact

Justin Hall

Chief Executive Officer and General Counsel

510-899-8800

jhall@novabay.com

Investor Contact

LHA Investor Relations

Jody Cain

310-691-7100

jcain@lhai.com

Source: NovaBay Pharmaceuticals, Inc.

FAQ

When will NovaBay Pharmaceuticals present at the Sequire Biotechnology Conference?

NovaBay Pharmaceuticals will present on February 2, 2023, at 2:30 p.m. Eastern time.

What product line is NovaBay focusing on in 2023?

In 2023, NovaBay is increasing its focus on effective wound care products.

When will NovaBay report its 2022 financial results?

NovaBay will report its 2022 fourth quarter and full year financial results on March 23, 2023.

What is the stock symbol for NovaBay Pharmaceuticals?

The stock symbol for NovaBay Pharmaceuticals is NBY.

How did NovaBay perform in Q4 2022?

NovaBay closed Q4 2022 with one of its best quarters ever for Avenova® unit sales.

NovaBay Pharmaceuticals, Inc.

NYSE:NBY

NBY Rankings

NBY Latest News

NBY Stock Data

2.41M
4.88M
0.02%
2.58%
3.83%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
EMERYVILLE